AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26174294
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at an estimated brain concentration of 0.90 μg ml(‐1)
Trial: 24450487
Drug: Extended combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended combined oral contraceptives
Trial: 19443528
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (SFC)
Trial: 12644803
Drug: D‐DBA technique
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D‐DBA technique (DBA applied immediately after preparations)
Trial: 12644803
Drug: No DBA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No DBA technique (no bonding agent used)
Trial: 7570509
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (3-4 times a week for 6 weeks, 20-30 minutes per session)
Trial: 7570509
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard rehabilitation therapy)
Trial: 1937998
Drug: Dilevalol 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilevalol 600 mg
Trial: 6130532
Drug: Atropine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (0.4 or 0.8 mg subcutaneous injections)
Trial: 6130532
Drug: Bethanechol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bethanechol (2.5 mg)
Trial: 6130532
Drug: 16,16-dimethyl prostaglandin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16,16-dimethyl prostaglandin E2 (DmPGE2, 7 to 140 ng/kg intravenous over five minutes)
Trial: 26961929
Drug: DHA plus
RxNorm normalized name: PNV-DHA Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA plus EPA (2 g/d)
Trial: 29023535
Drug: Carbohydrate‐electrolyte solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate‐electrolyte solution (CES, 6% carbohydrate)
Trial: 29023535
Drug: Carbohydrate‐electrolyte‐protein solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate‐electrolyte‐protein solution (CEPS, 2% protein plus 4% carbohydrate)
Trial: 29023535
Drug: Carbohydrate‐electrolyte‐protein solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate‐electrolyte‐protein solution (CEPS)
Trial: 12960117
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg EGCG once/day
Trial: 12960117
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg EGCG twice/day
Trial: 12960117
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg EGCG as Polyphenon E once/day
Trial: 12960117
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg EGCG as Polyphenon E twice/day
Trial: 15324531
Drug: Diclofenac 50
RxNorm normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 50 mg three times daily
Trial: 1394826
Drug: M-VAC therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M-VAC therapy (methotrexate, vinblastine, adriamycin, and cisplatin)
Trial: 1394826
Drug: M-VAC therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M-VAC therapy
Trial: 3871883
Drug: Propranolol 5
RxNorm normalized name: propranolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 5 mg every 6 hours orally (n = 82)
Trial: 30416083
Drug: Benralizumab 30
RxNorm normalized name: benralizumab 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab 30 mg Q4W
Trial: 30661249
Drug: Benralizumab 30
RxNorm normalized name: benralizumab 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab 30 mg Q8W
Trial: 15292326
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy for 6 months
Trial: 11573752
Drug: Medical Nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical Nutrition Therapy (MNT) from dietitians using a NCEP based lowering protocol
Trial: 9758087
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil (cand.cil.) 8 mg o.i.d. (increased to 16 mg o.i.d. if necessary)
Trial: 9758087
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil (cand.cil.) 8-16 mg o.i.d. for 12 weeks
Trial: 7522510
Drug: Dacarbazine (DTIC)
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dacarbazine (DTIC) based chemotherapy or chemoimmunotherapy
Trial: 2978286
Drug: 0.9% (w/v)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% (w/v) NaCl solution (saline)
Trial: 23208945
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy and exercise
Trial: 27998002
Drug: rBet v
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rBet v 1-FV allergen immunotherapy (AIT)
Trial: 26852502
Drug: Local ozone
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local ozone therapy
Trial: 26852502
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of local and general ozone therapy
Trial: 26852502
Drug: Basic therapy
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic therapy alone
Trial: 12952263
Drug: Lyso-PAF (L-PAF)
RxNorm normalized name: pafuramidine
DrugBank: Pafuramidine (DB06532)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyso-PAF (L-PAF)
Trial: 10649811
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen (CEE), 1.25 mg/d
Trial: 10649811
Drug: Esterified estrogens,
RxNorm normalized name: Esterified Estrogens, 1.25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esterified estrogens, 0.625 mg + methyltestosterone, 1.25 mg/d
Trial: 10649811
Drug: Esterified estrogens,
RxNorm normalized name: Esterified Estrogens, 1.25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esterified estrogens, 1.25 mg + methyltestosterone, 2.5 mg/d
Trial: 1986661
Drug: Flumazenil (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (up to 1 mg)
Trial: 25040613
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate (FF) 50 mcg once-daily
Trial: 25040613
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 100 mcg twice-daily
Trial: 18192544
Drug: Salbutamol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol plus AIR insulin (moderate asthma group only)
Trial: 8611060
Drug: Imipramine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine treatment combined with weekly relapse prevention psychotherapy
Trial: 1934862
Drug: Ciprofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (500 mg) with 300 ml water
Trial: 7073026
Drug: Isoetharine (1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoetharine (1% solution)
Trial: 7073026
Drug: Isoproterenol (0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol (0.5% solution)
Trial: 6734291
Drug: Dual screen
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual screen with annual chest x-ray examination and four monthly sputum cytology evaluation
Trial: 27484701
Drug: Dexmedetomidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.5 μg/kg loading dose infused over 10 min followed by a constant infusion of 0.5 μg/kg/h) added to propofol-remifentanil regimen (DP adjusted group)
Trial: 27484701
Drug: Dexmedetomidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.5 μg/kg loading dose infused over 10 min followed by a constant infusion of 0.5 μg/kg/h) added to propofol-remifentanil regimen (DP unadjusted group)
Trial: 25522403
Drug: Silexan (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silexan (160 mg daily for a minimum of 8 weeks)
Trial: 22460728
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (never used antacid medications)
Trial: 20394460
Drug: Pharmacist management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist management of diabetes (including medication management, patient education, and disease control)
Trial: 17498718
Drug: Ethanol-water solution
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol-water solution
Trial: 8739175
Drug: Braun/Oral-B Plak
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Braun/Oral-B Plak Control (D7)
Trial: 1756202
Drug: m-CPP (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m-CPP (0.5 mg/kg)
Trial: 21704493
Drug: Caffeine (480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (480 mg)
Trial: 1337607
Drug: Baclofen 5
RxNorm normalized name: baclofen 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen 5 mg
Trial: 1337607
Drug: Baclofen 10
RxNorm normalized name: baclofen 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen 10 mg
Trial: 7042732
Drug: Baclofen 20
RxNorm normalized name: baclofen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen 20 mg
Trial: 28193257
Drug: Prednisolone 1
RxNorm normalized name: prednisolone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 1 mg/kg/day to a maximum of 50 mg/day for 10 days
Trial: 22027927
Drug: ATG/Dac (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG/Dac (3 ATG, 2 Dac doses)
Trial: 22027927
Drug: ATG/alemtuzumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG/alemtuzumab (1 dose each)
Trial: 16827637
Drug: Azithromycin-containing toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin-containing toothpaste (85 mg azithromycin per gram, prescribed b.i.d., 1.5 cm for 1 month)
Trial: 15018588
Drug: Cetrorelix (0.25mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetrorelix (0.25mg daily injections or 3mg intermediate depot preparation)
Trial: 15018588
Drug: Ganirelix (0.25mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganirelix (0.25mg daily injections)
Trial: 15018588
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist multiple-dose protocol
Trial: 15018588
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist single-dose protocol
Trial: 15018588
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist cycles
Trial: 11371127
Drug: GnRH analogs
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH analogs (leuprolide acetate) administered prior to and during polychemotherapy (PCT)
Trial: 8192646
Drug: Composite index
RxNorm normalized name: DRESSING,COMPOSITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composite index for treatment outcome research with social phobia
Trial: 28053275
Drug: CRP (C-reactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP (C-reactive protein) increase (per 10 mg/l)
Trial: 28053275
Drug: Baseline creatinine
RxNorm normalized name: Creatinine
DrugBank: Creatinine (DB11846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline creatinine increase (per 100 µmol/l)
Trial: 21854503
Drug: SBR759 (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBR759 (3.0 or 4.5 g/day)
Trial: 21854503
Drug: Sevelamer hydrochloride
RxNorm normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevelamer hydrochloride (2.4 or 4.8 g/day)
Trial: 17971091
Drug: peginterferon α‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peginterferon α‐2a (40KD) 180μg/week plus ribavirin 1000/1200 mg/day for 48 weeks
Trial: 16947384
Drug: Abatacept (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept (10 mg/kg by weight range)
Trial: 16947384
Drug: Abatacept plus
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept plus biologic agent
Trial: 16947384
Drug: Other subgroups
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other subgroups (not receiving biologic agent)
Trial: 12969096
Drug: Methohexital plus
RxNorm normalized name: Methohexital
DrugBank: Methohexital (DB00474)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methohexital plus remifentanil (0.625 mg kg‐1 methohexital + 1 micro g kg‐1 remifentanil)
Trial: 12969096
Drug: Methohexital alone
RxNorm normalized name: Methohexital
DrugBank: Methohexital (DB00474)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methohexital alone (1.25 mg kg‐1)
Trial: 11885182
Drug: Non-HA-coated implants
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-HA-coated implants
Trial: 11885170
Drug: Implants mobile
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implants mobile at uncovering
Trial: 11885170
Drug: Implants with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implants with facial bone thickness >= 1.8 mm
Trial: 11885170
Drug: Implants that
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implants that failed to integrate
Trial: 11885170
Drug: HA-coated vs
RxNorm normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA-coated vs non-HA-coated implants
Trial: 9383226
Drug: Immediate administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate administration of G-CSF (day +1)
Trial: 9383226
Drug: Delayed, patient-dependent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed, patient-dependent G-CSF therapy (first day when ANC was below 0.5 x 10[9]/1)
Trial: 8463731
Drug: Topical prednisolone
RxNorm normalized name: prednisolone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical prednisolone phosphate 1.0% administered 4 times daily to the right eye
Trial: 8463731
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered to the left eye
Trial: 8463731
Drug: Topical prednisolone
RxNorm normalized name: prednisolone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical prednisolone phosphate 1.0%
Trial: 3534869
Drug: Captopril once
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril once daily (100 mg)
Trial: 3534869
Drug: Captopril twice
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril twice daily (50 mg)
Trial: 22132827
Drug: Amoxicillin trihydrate-potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin trihydrate-potassium clavulanate (Clavamox)
Trial: 20940176
Drug: Maternal plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal plasma levels of PFOS (ng/mL)
Trial: 20940176
Drug: Maternal plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal plasma levels of PFOA (ng/mL)
Trial: 18723709
Drug: Morphine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.1 mg/kg, max 10 mg over 5 min)
Trial: 8934257
Drug: Cyclical treatment
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclical treatment with 2 mg of oral estradiol valerate in combination with 250 micrograms of levonorgestrel for the last ten days (Cyclo Progynova)
Trial: 8934257
Drug: Continuous treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous treatment with 2 mg estradiol valerate orally in combination with a 20 micrograms per 24 hour levonorgestrel releasing intrauterine device
Trial: 8320744
Drug: DDATHF 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDATHF 3.0 mg/m2 per week
Trial: 8320744
Drug: DDATHF 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDATHF 4.5 mg/m2 per week
Trial: 8320744
Drug: DDATHF 6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDATHF 6.0 mg/m2 per week
Trial: 2883003
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg Epanolol-Visacor (ISA)
Trial: 2883003
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Metoprolol (without ISA)
Trial: 27363578
Drug: Warm needling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm needling therapy (GV14 and acupuncture at EX-HN3, ST2, LI20, EX-HN8, GV23, LU7, LU5, LI4) three times a week for 4 weeks
Trial: 27363578
Drug: Oral loratadine
RxNorm normalized name: loratadine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral loratadine 10 mg/day for 4 weeks
Trial: 24032192
Drug: Warm needling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm needling therapy
Trial: 18511016
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg oral estradiol (oE(2))
Trial: 18511016
Drug: 0.05 mg
RxNorm normalized name: biotin 0.05 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg transdermal estradiol (tE(2))
Trial: 8757574
Drug: Fentanyl infusion
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl infusion
Trial: 20368558
Drug: IFN‐alpha monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN‐alpha monotherapy
Trial: 12767369
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of surgery and immunotherapy
Trial: 12767369
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IFN‐alpha and Il‐2
Trial: 12767369
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IFN‐alpha, Il‐2 and 5‐fluorouracil (5‐FU)
Trial: 10493320
Drug: Flunisolide (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunisolide (1000 microg twice daily)
Trial: 10493320
Drug: Budesonide (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (1000 microg twice daily)
Trial: 10493320
Drug: Beclomethasone (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone (1000 microg twice daily)
Trial: 10493320
Drug: Triamcinolone (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamcinolone (1000 microg twice daily)
Trial: 10493320
Drug: Fluticasone (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone (1000 microg twice daily)
Trial: 972558
Drug: Drug profile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug profile provided to half of the study population for a full year.
Trial: 972558
Drug: No drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug profile provided (control group).
Trial: 21464262
Drug: Osteopathic manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manipulative treatment (OMT) for 20 minutes
Trial: 9024260
Drug: GHRH infusion
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH infusion (1 microgram/kg bolus at 0900 h, then 1 microgram/kg/h for 21 h)
Trial: 9024260
Drug: GHRP-2 infusion
RxNorm normalized name: Interleukin-2/diptheria toxin fusion protein
DrugBank: Denileukin diftitox (DB00004)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GHRP-2 infusion (1 microgram/kg bolus at 0900 h, then 1 microgram/kg/h for 21 h)
Trial: 9024260
Drug: GHRH plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH plus GHRP-2 infusion
Trial: 7898866
Drug: Early-treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early-treatment group (5-FU injections started 2.4 +/- 0.6 days postoperatively)
Trial: 7898866
Drug: Delayed-treatment group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-treatment group (5-FU injections started 12.6 +/- 5.4 days postoperatively)
Trial: 7898866
Drug: Early-treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early-treatment group
Trial: 7898866
Drug: Delayed-treatment group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-treatment group